Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest of Revance Therapeutics, Inc. from 31 Mar 2013 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Revance Therapeutics, Inc. quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD history and change rate from 31 Mar 2013 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending 30 Sep 2024 was $36,615,000, a 6.5% increase year-over-year.
Source SEC data
View on sec.gov
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Change (%)

Revance Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $36,615,000 +$2,530,000 +6.5% 01 Jul 2024 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q3 2023 $39,145,000 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q3 2021 $74,376,000 +$6,881,000 +8.5% 01 Jul 2021 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q3 2020 $81,257,000 01 Jul 2020 30 Sep 2020 10-Q 09 Nov 2021 2021 Q3
Q1 2014 $21,426,000 +$231,000 +1.1% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2014 2014 Q1
Q1 2013 $21,657,000 01 Jan 2013 31 Mar 2013 10-Q 14 May 2014 2014 Q1
* An asterisk sign (*) next to the value indicates that the value is likely invalid.